OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
Business Wire•17/08/2026•06:01 ET
0
Whiz Insights
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb’s technology platform and expertise in ion channel discovery and screening.
Get started
Create a free account to read the full story.